|
Next-generation targeted sequencing (NGTS) investigating CDK4 as a prognostic driver in pure invasive lobular breast carcinoma (ILC): Preliminary results in early-stage patients (pts) stratified according to a validated clinico-pathological model. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Celgene; Genomic Health |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Lilly |
Research Funding - Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Celgene |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Roche/Genentech |
Research Funding - Merck Serono; Novartis; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene; Merck Serono |
Travel, Accommodations, Expenses - Merck Serono; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Helsinn Healthcare; Lilly; MSD Oncology; Novartis; Pfizer; Roche (Inst) |
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |